125 related articles for article (PubMed ID: 18622267)
1. Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation.
Tabolacci E; De Pascalis I; Accadia M; Terracciano A; Moscato U; Chiurazzi P; Neri G
Pharmacogenet Genomics; 2008 Aug; 18(8):738-41. PubMed ID: 18622267
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni.
Dubois F; Caby S; Oger F; Cosseau C; Capron M; Grunau C; Dissous C; Pierce RJ
Mol Biochem Parasitol; 2009 Nov; 168(1):7-15. PubMed ID: 19538992
[TBL] [Abstract][Full Text] [Related]
3. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells.
Coffee B; Zhang F; Warren ST; Reines D
Nat Genet; 1999 May; 22(1):98-101. PubMed ID: 10319871
[TBL] [Abstract][Full Text] [Related]
4. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes.
Milutinovic S; D'Alessio AC; Detich N; Szyf M
Carcinogenesis; 2007 Mar; 28(3):560-71. PubMed ID: 17012225
[TBL] [Abstract][Full Text] [Related]
5. Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments.
Tabolacci E; Pietrobono R; Moscato U; Oostra BA; Chiurazzi P; Neri G
Eur J Hum Genet; 2005 May; 13(5):641-8. PubMed ID: 15741991
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene.
Chiurazzi P; Pomponi MG; Pietrobono R; Bakker CE; Neri G; Oostra BA
Hum Mol Genet; 1999 Nov; 8(12):2317-23. PubMed ID: 10545613
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modifications in valproic acid-induced teratogenesis.
Tung EW; Winn LM
Toxicol Appl Pharmacol; 2010 Nov; 248(3):201-9. PubMed ID: 20705080
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of histone deacetylase inhibitors and amphetamine on histone H4 acetylation, cAMP responsive element binding protein phosphorylation and DeltaFosB expression in the striatum and locomotor sensitization in mice.
Shen HY; Kalda A; Yu L; Ferrara J; Zhu J; Chen JF
Neuroscience; 2008 Dec; 157(3):644-55. PubMed ID: 18848971
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine.
Pietrobono R; Pomponi MG; Tabolacci E; Oostra B; Chiurazzi P; Neri G
Nucleic Acids Res; 2002 Jul; 30(14):3278-85. PubMed ID: 12136110
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome.
Brasa S; Mueller A; Jacquemont S; Hahne F; Rozenberg I; Peters T; He Y; McCormack C; Gasparini F; Chibout SD; Grenet O; Moggs J; Gomez-Mancilla B; Terranova R
Clin Epigenetics; 2016; 8():15. PubMed ID: 26855684
[TBL] [Abstract][Full Text] [Related]
11. Sustained expression of FMR1 mRNA from reactivated fragile X syndrome alleles after treatment with small molecules that prevent trimethylation of H3K27.
Kumari D; Usdin K
Hum Mol Genet; 2016 Sep; 25(17):3689-3698. PubMed ID: 27378697
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.
Marchion DC; Bicaku E; Daud AI; Sullivan DM; Munster PN
Cancer Res; 2005 May; 65(9):3815-22. PubMed ID: 15867379
[TBL] [Abstract][Full Text] [Related]
13. Valproic acid promotes neuronal differentiation by induction of proneural factors in association with H4 acetylation.
Yu IT; Park JY; Kim SH; Lee JS; Kim YS; Son H
Neuropharmacology; 2009 Feb; 56(2):473-80. PubMed ID: 19007798
[TBL] [Abstract][Full Text] [Related]
14. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys.
Torrioli M; Vernacotola S; Setini C; Bevilacqua F; Martinelli D; Snape M; Hutchison JA; Di Raimo FR; Tabolacci E; Neri G
Am J Med Genet A; 2010 Jun; 152A(6):1420-7. PubMed ID: 20503316
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors and candidate gene expression: An in vivo and in vitro approach to studying chromatin remodeling in a clinical population.
Gavin DP; Kartan S; Chase K; Jayaraman S; Sharma RP
J Psychiatr Res; 2009 Jun; 43(9):870-6. PubMed ID: 19187942
[TBL] [Abstract][Full Text] [Related]
16. Molecular diagnosis of Fragile X syndrome.
Sofocleous C; Kolialexi A; Mavrou A
Expert Rev Mol Diagn; 2009 Jan; 9(1):23-30. PubMed ID: 19099346
[TBL] [Abstract][Full Text] [Related]
17. The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro.
Tabolacci E; Pirozzi F; Gomez-Mancilla B; Gasparini F; Neri G
BMC Med Genet; 2012 Mar; 13():13. PubMed ID: 22397687
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics, fragile X syndrome and transcriptional therapy.
Tabolacci E; Chiurazzi P
Am J Med Genet A; 2013 Nov; 161A(11):2797-808. PubMed ID: 24123753
[TBL] [Abstract][Full Text] [Related]
19. Small Molecules Targeting H3K9 Methylation Prevent Silencing of Reactivated
Kumari D; Sciascia N; Usdin K
Genes (Basel); 2020 Mar; 11(4):. PubMed ID: 32230785
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic modifications of the FMR1 gene.
Tabolacci E; Neri G
Methods Mol Biol; 2013; 1010():141-53. PubMed ID: 23754224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
